- Home
- NCNO vs ZLAB Comparison
NCNO vs ZLAB Comparison
Compare NCNO & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NCNO | ZLAB |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.2B |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | NCNO | ZLAB |
|---|---|---|
| Price | $23.38 | $19.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 6 |
| Target Price | $33.40 | ★ $57.22 |
| AVG Volume (30 Days) | ★ 2.2M | 849.1K |
| Earning Date | 12-03-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $586,485,000.00 | $441,629,000.00 |
| Revenue This Year | $10.88 | $30.20 |
| Revenue Next Year | $8.53 | $34.71 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 12.14 | ★ 24.14 |
| 52 Week Low | $18.75 | $19.40 |
| 52 Week High | $40.29 | $44.34 |
Technical Indicators
Market Signals| Indicator | NCNO | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 35.75 | 25.39 |
| Support Level | $24.12 | $19.40 |
| Resistance Level | $27.50 | $20.47 |
| Average True Range (ATR) | 0.98 | 0.54 |
| MACD | -0.03 | 0.25 |
| Stochastic Oscillator | 0.93 | 8.06 |
Price Performance
Historical ComparisonAbout NCNO nCino Inc.
Ncino Inc is a provider of cloud-based software for financial institutions. Its software solution digitizes, automates, and streamlines inefficient and complex processes & workflows and utilizes data analytics & artificial intelligence that enables financial institutions to onboard new clients, make loans, and manage the entire loan life cycle, open deposits, and other accounts, and manage regulatory compliance. It also offers professional services, including configuration & implementation, training, and advisory services. The company generates the majority of its revenue from subscription services. The company caters to financial institutions, enterprise banks, regional banks, community banks, and credit unions. The vast majority of its revenue comes from the United States.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.